What does Granite Bio do?
Granite Bio is a clinical-stage immunology company developing novel antibodies that target the root causes of inflammatory, autoimmune, and fibrotic conditions.
How much did they raise?
The company raised a total of $100M, comprising a $30M Series A round led by Versant Ventures and Novartis Venture Fund, and a $70M Series B round led by Forbion and Sanofi Ventures.
What are their plans for the money?
The funds will be used to expand operations and boost R&D efforts, potentially accelerating the development of first-in-class antibody therapies for large market autoimmune diseases.
What have they achieved so far?
Granite Bio has already made progress with a pipeline featuring two first-in-class antibodies aimed at addressing multiple autoimmune diseases.
